Instead, the cap would shift costs to others through higher insurance premiums and copays, the group said in a March 31 news release.
The group said it supports real solutions to drug affordability and blamed the pharmaceutical industry for high insulin prices.
“Rather than holding Big Pharma accountable, this legislation continues to empower Big Pharma to raise insulin prices with impunity, leaving patients, businesses, and hardworking taxpayers paying even more for healthcare,” the group said.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 17–19 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
